Boston Scientific Estimates Net Sales Growth For Q1 2024 Of Approximately 7.5%-9.5% Y/Y On A Reported Basis, And Approximately 7%-9% On An Organic Basis. The Company Sees Adjusted EPS Of $0.50-$0.52 Versus Consensus Of $0.52
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific projects Q1 2024 net sales growth of 7.5%-9.5% year-over-year on a reported basis, and 7%-9% on an organic basis. The company anticipates adjusted EPS to be between $0.50 and $0.52, which is in line with the consensus estimate of $0.52.
January 31, 2024 | 11:45 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Boston Scientific expects Q1 2024 net sales growth of 7.5%-9.5% Y/Y and adjusted EPS of $0.50-$0.52, matching consensus estimates.
The projected sales growth and EPS for Boston Scientific are in line with consensus estimates, suggesting that the market has likely already priced in these expectations. Therefore, the short-term impact on the stock price may be neutral, as there are no significant positive or negative surprises.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100